<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836637</url>
  </required_header>
  <id_info>
    <org_study_id>M236</org_study_id>
    <nct_id>NCT04836637</nct_id>
  </id_info>
  <brief_title>ValoRization of Dairy Sidestreams to Fight Calcium dEficits iN Postmenopausal Women</brief_title>
  <acronym>RENEW</acronym>
  <official_title>ValoRization of Dairy Sidestreams to Fight Calcium dEficits iN Postmenopausal Women - A Randomized Controlled Double-blinded Intervention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the effects of 12-months&#xD;
      supplementation with calcium-enriched permeate, taken alone or in conjunction with inulin, on&#xD;
      changes in markers of bone formation and resorption and in bone mass density (BMD) in&#xD;
      apparently healthy postmenopausal women compared with calcium-carbonate or maltodextrin&#xD;
      supplementation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include an information visit, a randomization visit, a month 3 visit and a&#xD;
      final visit at month 12. Besides, two visits at month 6 and 9 for dispensing of trial&#xD;
      products. Outcome parameters will be measured using blood samples obtained at the&#xD;
      randomization visit, the month 3 visit and at the final visit at month 12. Outcome parameters&#xD;
      will moreover be analyzed based on DXA scan obtained at the randomization visit and at the&#xD;
      final visit at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in bone turnover marker CTX.</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in fasting blood samples of bone turnover marker CTX attained at randomization, 3-months visit and 1 year-visit (final visit)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in bone turnover marker P1NP.</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in fasting blood samples of bone turnover marker (P1NP) attained at randomization, 3-months and 1 year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in loss of bone mineral density.</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in DXA scan results of BMD (femur) and BMD (lumbar spine) attained at randomization and final visit (1 year).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood parameters of iPTH</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in fasting blood samples of iPTH attained at randomization and final visit (1 year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood parameters of Vitamin D</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in fasting blood samples of vitamin D attained at randomization and final visit (1 year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood parameters of total calcium</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in fasting blood samples of total calcium attained at randomization and final visit (1 year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood parameters of phosphate</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in fasting blood samples of phosphate attained at randomization and final visit (1 year)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in BMI</measure>
    <time_frame>1 year</time_frame>
    <description>Changes from randomization to final visit at 12 months in BMI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in physical activity</measure>
    <time_frame>1 year</time_frame>
    <description>Changes from randomization to final visit at 12 months in physical activity level attained by IPAQ.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in habitual dietary intake</measure>
    <time_frame>1 year</time_frame>
    <description>Changes from randomization to final visit at 12 months in habitual dietary intake attained by Myfood24 7-day recording.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Product with placebo (no calcium supplementation).</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin with 0 mg calcium in capsules and sachets consumed orally daily for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product with calcium-carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 mg calcium as calcium-carbonate in capsules and sachets consumed orally daily for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product with calcium-enriched permeate &quot;Capolac&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg of calcium from calcium-enriched permeate in capsules and sachets consumed orally daily for one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product with calcium-enriched permeate &quot;Capolac&quot; and Inulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg of calcium from calcium-enriched permeate and 12 g inulin in capsules and sachets consumed orally daily for one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.</description>
    <arm_group_label>Product with placebo (no calcium supplementation).</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium-carbonate</intervention_name>
    <description>Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.</description>
    <arm_group_label>Product with calcium-carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium-enriched permeate</intervention_name>
    <description>Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.</description>
    <arm_group_label>Product with calcium-enriched permeate &quot;Capolac&quot;</arm_group_label>
    <other_name>Capolac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium-enriched permeate with Inulin</intervention_name>
    <description>Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.</description>
    <arm_group_label>Product with calcium-enriched permeate &quot;Capolac&quot; and Inulin</arm_group_label>
    <other_name>Capolac Inulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is between 45 years and 65 years of age by the time of inclusion.&#xD;
&#xD;
          -  Subject has been menopausal for at least 1 year, defined as 12 months after last&#xD;
             bleeding and up to 10 years.&#xD;
&#xD;
          -  Subject is Caucasian.&#xD;
&#xD;
          -  Has a BMI below 35.0.&#xD;
&#xD;
          -  Holder of a computer.&#xD;
&#xD;
          -  Has a sufficient vitamin D status (plasma 25OHD concentration &gt; 50 nmol/L).&#xD;
&#xD;
          -  Subject is willing and able to provide written informed consent prior to&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject taking supplements or medicine that affects calcium and bone metabolism e.g.&#xD;
             diuretics or hormone replacement therapy evaluated by the investigator.&#xD;
&#xD;
          -  Intake of antibiotics in the last 3 months before enrollment.&#xD;
&#xD;
          -  Subject with an osteoporosis diagnosis or history of osteoporotic fractures.&#xD;
&#xD;
          -  Presence of renal, gastrointestinal, hepatic or endocrinological diseases.&#xD;
&#xD;
          -  Subject with any serious illness or history of cancer within the past 5 years (except&#xD;
             adequately-treated localized basal cell skin cancer or in situ uterine cervical&#xD;
             cancer).&#xD;
&#xD;
          -  Known or suspected abuse of alcohol or recreational drugs.&#xD;
&#xD;
          -  Known milk allergy.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial products or related products.&#xD;
&#xD;
          -  Blood donation except from the donation in this study.&#xD;
&#xD;
          -  Subject where it is not possible to obtain sufficient data.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette F Hitz, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zealand University Hospital, Køge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inge Tetens, Professor</last_name>
    <phone>+4551157480</phone>
    <email>ite@nexs.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Majbritt H Hare, PhD student</last_name>
    <phone>+40733001</phone>
    <email>mhh@nexs.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University, Department of Nutrition, Exercise and Sports, Section for Clinical and Preventive Nutrition</name>
      <address>
        <city>Copenhagen</city>
        <state>Frederiksberg</state>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Tetens, Professor</last_name>
      <phone>+4551157480</phone>
      <email>ite@nexs.ku.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette F Hitz, Doctor</last_name>
      <phone>004547322512</phone>
      <email>mefh@regionsjaelland.dk</email>
    </contact>
    <contact_backup>
      <last_name>Majbritt H Hare, PhD student</last_name>
      <phone>0045407330001</phone>
      <email>mhh@nexs.ku.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Inge Tetens</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The results will be analyzed and attempted published in international journals regardsless of whether the study leads to positive, negative or inconclusive results. The study protocol will be registered and made publicly avalailable at www.clinicaltrials.gov.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

